Daiichi Sankyo (DSNKY) Expected to Release Earnings on Friday

Daiichi Sankyo (OTCMKTS:DSNKY) is projected to issue its resultson Friday, July 31st. Analysts expect the company to announce earnings of $0.2608 per share and revenue of $3.3434 billion for the quarter. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.74 billion. On average, analysts expect Daiichi Sankyo to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Daiichi Sankyo Trading Up 2.6%

DSNKY opened at $17.87 on Wednesday. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $27.50. The company has a fifty day moving average of $16.47 and a 200-day moving average of $17.81. The stock has a market cap of $33.29 billion, a PE ratio of 19.01, a price-to-earnings-growth ratio of 3.05 and a beta of -0.17. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, Daiichi Sankyo presently has an average rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.